

DISCLOSURE OF RELEVANT RELATIONSHIPS & CONFIDENTIALITY STATEMENTS

For NIA-AA Guidelines Workgroup

Confidential

DISCLOSURE OF RELEVANT RELATIONSHIPS

For each of the categories below, (1) please disclose relationships that cover the last 12 months and for anticipated activities in the coming 12 months as of approximately April 2016. If you have none, please write "none." Relationships apply to you and to spouse or dependent children. (2) For each relationship, please indicate whether it is a "**Significant (\geq \$1,000) Financial Interest**" Financial interests include but are not limited to salary, consulting and / or speaker fees, honoraria, research support, equity interests (e.g., stocks, stock options, or other ownership interests), and intellectual property rights (e.g., patents, copyrights and royalties from such rights).

1. Research funding (federal, foundation and corporate) relevant to the topic of Alzheimer's disease. NIH grants: R01 NS090934, R01AG047644, R01AG04867801, P01NS074969, P01 NS080675, P01 AG03991, R01-NS034467, U01AG032438, P01 AG026276; The Tau Consortium, The JPB Foundation, research grants from these companies: C2N Diagnostics, Eli Lilly, Denali, AbbVie For all the grants above, there is a significant financial interest.

2. Consulting to a for-profit company (paid and unpaid) relevant to the topic of Alzheimer's disease.

Consulting for Genentech, Denali, AbbVie, Eli Lilly, Proclara Biosciences, Glaxosmithkline For all the consulting relationships above, there is a significant financial interest

3. Ownership of property relevant to the topic of Alzheimer's disease (patents filed or approved, licenses and other property shares) -- for each, please indicate whether you do or do not accept royalties.

David Holtzman is an Inventor on these patents below. Washington University filed all these patents and accepts royalties on all of them.

Predictive Diagnostic for Alzheimer's Disease, US patent number 6,465,195

Humanized Antibodies that Sequester ABeta Peptide, US patent number 7,195,761

Humanized antibodies that sequester amyloid beta peptide, US patent number 7,892,545

Diagnostic for early stage Alzheimer's Disease, US patent number 7,015,044

Assay method for Alzheimer's disease, US patent 7,771,722

Methods for measuring the metabolism of neutrally derived biomolecules in vivo, US patent 7,892,845

Use of Anti-AB antibody to treat traumatic brain injury, Pub App no 20090074775

Methods to treat Alzheimer's disease or other disorders mediated by amyloid-beta accumulation in a subject. Pub App no. 20092643555

Alzheimer's disease biomarkers and methods of use, Pub App no. 20110143380

Risk factors and a therapeutic target for neurodegenerative disorders, Pub App no. 20110177509

Methods for diagnosing Alzheimer's disease, Pub App no. 20140370619

Altering protein concentration in cerebrospinal fluid and/or brain interstitial fluid , Pub App no. 20140377319

Antibodies to tau, Pub App no. 20150183855

Compositions and methods for treating amyloid plaque associated symptoms, Pub App no. 20160355581

Methods for detecting amyloid beta amyloidosis, Pub App no. 20160178646

Methods of determining amyloid beta turnover in blood, Pub App no. 20170146557

4. Equity in companies whose work is relevant to the topic of Alzheimer's disease

Equity in C2N Diagnostics, LLC, there is a significant financial interest

5. Employment in companies whose work is relevant to the topic of Alzheimer's disease

none

6. Relevant scientific work to the NIA-AA Workgroup discussions.

Virtually all of my scientific work is relevant to the topics being discussed by the NIA-AA workshops

I will immediately notify NIA-AA Workgroup leads if a change occurs in any of the above during the tenure of my responsibilities,

David Holtzman



8-15-17

Name

Signature

Date